Illinois-based Green Thumb Industries (GTI) (CSE:GTII,OTCQX:GTBIF) saw a solid market opening on Thursday (November 21) following the release of its earnings report for Q3 2019.

Shares were up 2.7 percent on Thursday from the market close on Wednesday (November 20) and prices currently sit at C$13.18 as of 3:36 p.m. EST.

At the end of the trading day on Wednesday, GTI boasted a quarter-over-quarter revenue increase of 52 percent to US$68 million in its report, driven by growth in its consumer products and retail businesses, the company said.

In its home state, CEO Ben Kovler told investors and analysts during a call that GTI plans to have at least three adult-use retail stores open in Illinois on January 1, 2020, the day the sale and use of recreational cannabis becomes legal state-wide.

Illinois’ upcoming recreational cannabis sector is projected to rival Colorado’s once it finds its footing, raking in a possible U$2 billion a year, according to Marijuana Business Daily.

“The tidal wave of demand you have heard me mention over the last year is about to hit Illinois hard,” said Kovler.

The company also attributed revenue growth to a full quarter of business for its acquisition, Integral Associates, which owns the Essence line of cannabis stores in Las Vegas, Nevada.

Kovler said that medical-only Pennsylvania doubled in size over the last quarter, further contributing to the firm’s revenue growth.

GTI reported a reduction in its net loss for the third quarter to US$17.1 million from the US$22.2 million reported in Q2 2019. Earnings before interest, tax, depreciation and amortization hit US$1.6 million, up from a loss of US$9.4 million from the previous recording period.

image of GTI's stock market fluctuationConsumer brands proved to be a boon for GTI this quarter, as branded product sales grew 50 percent in the eight markets it currently operates in, including California, Colorado and Florida.

GTI could come up against problems in one of its other operating states moving into 2020, however. CFO Anthony Georgiadis said that while GTI has a strong presence in Massachusetts, the firm is facing supply issues.

“We could probably service all the stores in the state but the reality is we wouldn’t do a great job because we just don’t have the product available to do so,” said Georgiadis.

Kovler went on to say GTI’s balance sheet, which includes US$66.1 million in cash, along with the firm’s retail operations will help GTI achieve its goal of over US$200 million in total revenue for its fiscal 2019 year.

When asked about the revenue goal, Kovler said retail, as well as cultivation and wholesale production, would be key drivers of growth of the company for the rest of the fiscal year. The executive didn’t specify which states GTI was focused on moving into 2020.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less